<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6539">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01898403</url>
  </required_header>
  <id_info>
    <org_study_id>MEL0010</org_study_id>
    <secondary_id>NCI-2013-01286</secondary_id>
    <secondary_id>27319</secondary_id>
    <secondary_id>P30CA124435</secondary_id>
    <nct_id>NCT01898403</nct_id>
  </id_info>
  <brief_title>Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma</brief_title>
  <official_title>Testing the Efficacy of Indocyanine Green Imaging ( ICG-SPY ) in the Identification of Sentinel Lymph Nodes ( SLN ) in Patients With Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies lymph node mapping using indocyanine green solution in
      diagnosing patients with malignant melanoma. Diagnostic procedures, such as lymph node
      mapping using indocyanine green solution, may help find out how far the melanoma has spread
      and may help in planning cancer treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To show that indocyanine green (ICG) (indocyanine green solution) is equal to both
      isosulfan blue (ISB) and technetium Tc 99m sulfur colloid (TSC) and will allow all lymph
      node mapping to occur in the operating room (OR).

      OUTLINE:

      Patients receive peri-tumoral, intradermal injections of isosulfan blue and indocyanine
      green solution. During surgery, patients undergo identification of the sentinel lymph node
      and imaging using a laser with videocamera (SPY Elite camera).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Mapping of the Sentinel Lymph Nodes (SLN)</measure>
    <time_frame>Up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>SLN will be identified and mapped using indocyanine green solution, isosulfan blue, and TSC. Participants will undergo peri-tumoral, intradermal injection of ISB AND ICG, in addition intra-operatively the SPY camera will be ued to identify SLN and take images.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Recurrent Melanoma</condition>
  <condition>Stage IA Melanoma</condition>
  <condition>Stage IB Melanoma</condition>
  <condition>Stage IIA Melanoma</condition>
  <condition>Stage IIB Melanoma</condition>
  <condition>Stage IIC Melanoma</condition>
  <condition>Stage IIIA Melanoma</condition>
  <condition>Stage IIIB Melanoma</condition>
  <condition>Stage IIIC Melanoma</condition>
  <condition>Stage IV Melanoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (indocyanine green solution, isosulfan blue)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive peri-tumoral, intradermal injections of isosulfan blue and indocyanine green solution. During surgery, patients undergo identification of the sentinel lymph node and imaging using a laser with videocamera (SPY Elite camera).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indocyanine green solution</intervention_name>
    <description>Given peri-tumoral and intradermally</description>
    <arm_group_label>Diagnostic (indocyanine green solution, isosulfan blue)</arm_group_label>
    <other_name>IC-GREEN</other_name>
    <other_name>ICG solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isosulfan blue</intervention_name>
    <description>Given peri-tumoral and intradermally</description>
    <arm_group_label>Diagnostic (indocyanine green solution, isosulfan blue)</arm_group_label>
    <other_name>Lymphazurin</other_name>
    <other_name>N-[4-[4-(diethylamino)phenyl] (2,5-disulfophenyl) Methylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium hydroxide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lymph node mapping</intervention_name>
    <description>Undergo lymph node mapping</description>
    <arm_group_label>Diagnostic (indocyanine green solution, isosulfan blue)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sentinel lymph node biopsy</intervention_name>
    <description>Undergo SNLB</description>
    <arm_group_label>Diagnostic (indocyanine green solution, isosulfan blue)</arm_group_label>
    <other_name>sentinel node biopsy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to understand and willingness to sign informed consent document

          -  Signed written informed consent

          -  Patients with malignant melanoma (MM) undergoing sentinel lymph node biopsy (SNLB)

          -  Complete blood count (CBC) and metabolic panel within 6 months

        Exclusion Criteria:

          -  History of hepatic or renal failure

          -  Allergy to iodine containing products

          -  Patients who are pregnant or may be pregnant

          -  Patients with psychiatric or addictive disorders that in the opinion of the research
             team, may not be able to meet study requirements
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph Greco</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University Hospitals and Clinics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Hospitals and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph S. Greco</last_name>
      <phone>650-736-1355</phone>
      <email>grecors@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Ralph S. Greco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>July 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
